University of Texas's MD Anderson Cancer Center: Study Discovers Triple Immunotherapy Combination As Possible Treatment For Pancreatic Cancer
December 31, 2022
December 31, 2022
HOUSTON, Texas, Dec. 31 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Dec. 30, 2022:
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, that successfully reprogrammed the tumor immune microenvironment (TIME) and significantly improved anti-tumor responses in preclinical models of pancreatic ca . . .
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, that successfully reprogrammed the tumor immune microenvironment (TIME) and significantly improved anti-tumor responses in preclinical models of pancreatic ca . . .